Advances in cancer immunotherapy 2019 -latest trends, J Exp Clin Cancer Res, vol.38, p.268, 2019. ,
Vaccine adjuvants: mode of action, Front Immunol, vol.4, p.214, 2013. ,
Current challenges for cancer vaccine adjuvant development, Exp Rev Vaccines, vol.17, pp.207-222, 2018. ,
Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes, Clin Exp Vaccine Res, vol.4, pp.23-45, 2015. ,
From synthetic polyelectrolytes to polymer-subunit vaccines, Pure Appl Chem, vol.76, pp.1659-77, 2004. ,
The safety profile of Polyoxidonium in daily practice: results from postauthorization safety study in Slovakia, Immunotherapy, vol.10, pp.131-138, 2018. ,
Study of interaction between the polyoxidonium immunomodulator and the human immune system cells, Int Immunopharmacol, vol.4, pp.1615-1638, 2004. ,
Effect of polyoxidonium on the phagocytic activity of human peripheral blood leukocytes, Russ J Immunol, vol.8, pp.53-60, 2003. ,
Influence of an immunopotentiator Polyoxidonium on cytokine profile and antibody production in children vaccinated with Priorix, Arch Physiol Biochem, vol.118, pp.197-203, 2012. ,
A team effort: natural killer cells on the first leg of the tumor immunity relay race, J Immunother Cancer, vol.6, p.67, 2018. ,
Improving the TNM classification: findings from a 10-year continuous literature review, Int J Cancer, vol.135, pp.371-379, 2014. ,
Degree of manifestation of therapeutic pathomorphosis and the nature of the change in the estrogen and progesterone receptors after the radiation and chemotherapy of breast cancer ,
, Vopr Onkol, vol.31, pp.69-73, 1985.
The use of 1H-NMR spectroscopy for predicting the efficiency of neoadjuvant chemotherapy of breast cancer, Bull Exp Biol Med, vol.130, pp.701-705, 2000. ,
Expansion of allogeneic NK cells with efficient antibodydependent cell cytotoxicity against multiple tumor cells, Theranostic, vol.8, pp.3856-69, 2018. ,
NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment, Oncoimmunology, vol.7, p.1409322, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01780378
Protein kinase Ctheta is required for NK cell activation and in vivo control of tumor progression, J Immunol, vol.182, pp.1972-81, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-02194087
Human NK cells activated by EBV lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells, Oncoimmunology, vol.4, p.991613, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01835574
From tumor cell metabolism to tumor immune escape, Int J Biochem Cell Biol, vol.45, pp.106-119, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00726717
Protein kinase C-theta (PKC-theta) in natural killer cell function and antitumor immunity, Front Immunol, vol.3, p.187, 2012. ,
Human NK cell diversity in viral infection: ramifications of ramification, Front Immunol, vol.7, p.66, 2016. ,
Identification of anti tumor cells carrying natural killer (NK) cell antigens in patients with hematological cancers, EBioMedicine, vol.2, pp.1364-76, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01867114
CD45 isoform profile identifies natural killer (NK) subsets with differential activity, PLoS ONE, vol.11, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01867110
Molecular mechanisms of natural killer cell activation, J Innate Immun, vol.3, pp.216-242, 2011. ,
CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells, Blood, vol.116, pp.1299-307, 2010. ,
CD57 defines a functionally distinct population of mature NK cells in the human CD56 dim CD16 + NK-cell subset, Blood, vol.116, pp.3865-74, 2010. ,
Natural killer cells: development, maturation, and clinical utilization, Front Immunol, vol.9, p.1869, 2018. ,
Cloning of three human tyrosine phosphatases reveals a multigene family of receptorlinked protein-tyrosine-phosphatases expressed in brain, Proc Natl Acad Sci, vol.87, pp.7000-7004, 1990. ,
Drug response to PD-1/PD-L1 blockade: based on biomarkers, OncoTargets Ther, vol.11, pp.4673-83, 2018. ,
Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review, Contemp Clin Trials Commun, vol.11, pp.156-64, 2018. ,
Role of adjuvants in modeling the immune response, Curr Opin HIV AIDS, vol.5, pp.409-422, 2010. ,
Protein tyrosine phosphatases in lymphocyte activation and autoimmunity, Nat Immunol, vol.13, pp.439-486, 2012. ,
Protein tyrosine phosphatases and the immune response, Nat Rev Immunol, vol.5, pp.43-57, 2005. ,
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol, vol.26, pp.1275-81, 2008. ,